MX2015002467A - Regimen de dosificacion de un sedante. - Google Patents

Regimen de dosificacion de un sedante.

Info

Publication number
MX2015002467A
MX2015002467A MX2015002467A MX2015002467A MX2015002467A MX 2015002467 A MX2015002467 A MX 2015002467A MX 2015002467 A MX2015002467 A MX 2015002467A MX 2015002467 A MX2015002467 A MX 2015002467A MX 2015002467 A MX2015002467 A MX 2015002467A
Authority
MX
Mexico
Prior art keywords
hypnotic
administering
sedative agent
methyl
general anesthesia
Prior art date
Application number
MX2015002467A
Other languages
English (en)
Inventor
Maki Kondo
Toshihiko Konomi
Shigehito Sato
Matsuyuki Doi
Original Assignee
Paion Uk Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Paion Uk Ltd filed Critical Paion Uk Ltd
Publication of MX2015002467A publication Critical patent/MX2015002467A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/55131,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/55171,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4468Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Anesthesiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Al administrar a un paciente por vía intravenosa un sedante que comprende 3-[(4S)-8-bromo-1-metil-6-(2-piridinil)-4H-imidazo [1,2-a] [1,4] benzodiazepin-4il] propanoato de metilo o una de sus sales mediante un régimen de dosificación que incluye un proceso de dos pasos descrito en la presente invención, se puede inducir la anestesia general de forma rápida y segura.
MX2015002467A 2012-08-31 2013-08-30 Regimen de dosificacion de un sedante. MX2015002467A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2012192081 2012-08-31
PCT/JP2013/073414 WO2014034890A1 (ja) 2012-08-31 2013-08-30 催眠鎮静剤の投与方式

Publications (1)

Publication Number Publication Date
MX2015002467A true MX2015002467A (es) 2015-11-09

Family

ID=50183693

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015002467A MX2015002467A (es) 2012-08-31 2013-08-30 Regimen de dosificacion de un sedante.

Country Status (34)

Country Link
US (2) US20150224114A1 (es)
EP (1) EP2891494B1 (es)
JP (1) JP6199869B2 (es)
KR (1) KR102228598B1 (es)
CN (1) CN104768557A (es)
AP (1) AP2015008287A0 (es)
AU (1) AU2013309860B2 (es)
BR (1) BR112015004477A8 (es)
CA (1) CA2883667A1 (es)
CL (1) CL2015000494A1 (es)
DK (1) DK2891494T3 (es)
EA (1) EA027370B1 (es)
ES (1) ES2959499T3 (es)
FI (1) FI2891494T3 (es)
GE (1) GEP201706755B (es)
HK (1) HK1210588A1 (es)
HR (1) HRP20231302T1 (es)
HU (1) HUE063967T2 (es)
IL (1) IL237373B (es)
LT (1) LT2891494T (es)
MA (1) MA37954A1 (es)
MX (1) MX2015002467A (es)
MY (1) MY171592A (es)
NZ (1) NZ705177A (es)
PE (1) PE20151374A1 (es)
PH (1) PH12015500381B1 (es)
PL (1) PL2891494T3 (es)
PT (1) PT2891494T (es)
SG (1) SG11201501358SA (es)
SI (1) SI2891494T1 (es)
TN (1) TN2015000067A1 (es)
UA (1) UA116452C2 (es)
WO (1) WO2014034890A1 (es)
ZA (1) ZA201501207B (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20170091770A (ko) 2006-07-10 2017-08-09 파이온 유케이 리미티드 속효형 벤조디아제핀 염 및 이의 중합체 형태
EP2305647A1 (en) 2009-09-18 2011-04-06 PAION UK Limited Process for preparing 3-[(4S)-8-bromo-1-methyl-6-(2-pyridinyl)-4 H-imidazo[1,2-a][1,4]benzodiazepine-4-yl] propionic acid methyl ester or the benzene sulfonate salt thereof, and compounds useful in that process
EP2450039A1 (en) 2010-11-08 2012-05-09 PAION UK Ltd. Dosing regimen for sedation with CNS 7056 (Remimazolam)
AR094963A1 (es) 2013-03-04 2015-09-09 Ono Pharmaceutical Co Reacción de oxidación excelente en el índice de conversión
PL3162804T3 (pl) * 2014-07-23 2020-04-30 Jiangsu Nhwaluokang Pharmaceutical Research And Development Co., Ltd. Nowa pochodna benzodiazepiny i jej zastosowanie
CN105130996B (zh) * 2015-08-07 2017-05-03 成都倍特药业有限公司 苯并二氮杂*衍生物的1,5‑萘二磺酸盐及晶型和它们的制备方法
CN107266452A (zh) * 2016-04-08 2017-10-20 四川科伦药物研究院有限公司 苯并二氮杂*衍生物的盐及其晶体形式、制备方法和用途
AU2017248683A1 (en) * 2016-04-14 2018-10-25 Paion Uk Limited Orally inhaled and nasal benzodiazepines
CN108503644B (zh) * 2016-12-09 2019-06-14 成都倍特药业有限公司 一种苯并二氮杂*衍生物的氢溴酸盐及其制备方法和用途
CN108033964B (zh) * 2017-12-28 2021-02-09 杭州奥默医药股份有限公司 一种吡啶基咪唑并苯并二氮杂卓丙酸酯化合物及其合成和应用
EP3714884A1 (en) 2019-03-27 2020-09-30 Paion UK Limited Medical uses for benzodiazepines with a particular eeg pattern
CN114478535B (zh) * 2020-10-23 2024-02-09 成都苑东生物制药股份有限公司 一种苯磺酸瑞马唑仑ii晶型的制备方法
JP2022108079A (ja) * 2021-01-12 2022-07-25 日本光電工業株式会社 生体情報処理装置、生体情報処理方法、プログラム及び記憶媒体
CN114588164B (zh) * 2022-04-19 2023-08-11 天津医科大学总医院 瑞马唑仑在预防围术期低体温和寒战中的应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9911152D0 (en) 1999-05-14 1999-07-14 Glaxo Group Ltd Short-acting benzodiazepines
KR20170091770A (ko) 2006-07-10 2017-08-09 파이온 유케이 리미티드 속효형 벤조디아제핀 염 및 이의 중합체 형태
GB0613693D0 (en) 2006-07-10 2006-08-16 Cenes Ltd Benzodiazepine salts (3)
EP2305647A1 (en) 2009-09-18 2011-04-06 PAION UK Limited Process for preparing 3-[(4S)-8-bromo-1-methyl-6-(2-pyridinyl)-4 H-imidazo[1,2-a][1,4]benzodiazepine-4-yl] propionic acid methyl ester or the benzene sulfonate salt thereof, and compounds useful in that process
EP2450039A1 (en) * 2010-11-08 2012-05-09 PAION UK Ltd. Dosing regimen for sedation with CNS 7056 (Remimazolam)

Also Published As

Publication number Publication date
HK1210588A1 (en) 2016-04-29
IL237373B (en) 2020-05-31
SG11201501358SA (en) 2015-04-29
PH12015500381A1 (en) 2015-04-20
HRP20231302T1 (hr) 2024-02-02
EP2891494B1 (en) 2023-07-19
ES2959499T3 (es) 2024-02-26
MY171592A (en) 2019-10-21
EP2891494A1 (en) 2015-07-08
WO2014034890A1 (ja) 2014-03-06
TN2015000067A1 (en) 2016-06-29
PL2891494T3 (pl) 2024-01-03
KR20150047573A (ko) 2015-05-04
CA2883667A1 (en) 2014-03-06
AU2013309860A1 (en) 2015-03-19
BR112015004477A2 (pt) 2017-07-04
PT2891494T (pt) 2023-10-25
UA116452C2 (uk) 2018-03-26
JP6199869B2 (ja) 2017-09-20
ZA201501207B (en) 2019-11-27
US20220152045A1 (en) 2022-05-19
LT2891494T (lt) 2023-11-10
US20150224114A1 (en) 2015-08-13
FI2891494T3 (fi) 2023-10-16
NZ705177A (en) 2018-01-26
PH12015500381B1 (en) 2015-04-20
EA201590467A1 (ru) 2015-07-30
AU2013309860B2 (en) 2017-12-21
KR102228598B1 (ko) 2021-03-15
BR112015004477A8 (pt) 2019-08-27
SI2891494T1 (sl) 2023-12-29
CN104768557A (zh) 2015-07-08
GEP201706755B (en) 2017-10-25
DK2891494T3 (da) 2023-10-23
IL237373A0 (en) 2015-04-30
EA027370B1 (ru) 2017-07-31
AP2015008287A0 (en) 2015-02-28
PE20151374A1 (es) 2015-09-25
CL2015000494A1 (es) 2015-10-02
MA37954A1 (fr) 2018-07-31
HUE063967T2 (hu) 2024-02-28
JPWO2014034890A1 (ja) 2016-08-08
EP2891494A4 (en) 2016-04-27

Similar Documents

Publication Publication Date Title
TN2015000067A1 (en) Method for administering hypnotic/sedative agent
UA115139C2 (uk) Спосіб доставки фармацевтичної композиції, яка містить омепразол й ацетилсаліцилову кислоту, пацієнту
MX2015002669A (es) Metodos de administracion de tratamiento con pirfenidona.
IN2014MN01755A (es)
MX361858B (es) Formulación oftálmica de lípido polioxilo o de ácido graso polioxilo y tratamiento de padecimientos oculares.
NZ713868A (en) Treatment of cancer using coenzyme q10 combination therapies
WO2012023623A3 (ja) ハンター症候群の治療剤
IN2014MN02214A (es)
MX2022001966A (es) 7-bencil-4-(2-metilbencil)-2,4,6,7,8,9- hexahidroimidazo[1,2-a]pir ido[3,4-e]pirimidin-5(1h)-ona, sales de la misma y metodos de uso.
MX366076B (es) Vitamina d3 y analogos de la misma para tratar alopecia.
MX2014008284A (es) Formulacion de liberacion retardada para reducir la frecuencia de orinar y metodos de uso de esta.
IN2014DN08598A (es)
WO2012145575A3 (en) Therapy for leukemia
EP3162804A8 (en) New benzodiazepine derivative and use thereof
MX2019008817A (es) Formulacion de liberacion prolongada para reducir la frecuencia de miccion y metodo de uso de la misma.
MX348418B (es) Composicion ocular que contiene bromfenaco con biodisponibilidad incrementada.
IN2014DN10134A (es)
EA032959B1 (ru) Применение бремеланотида в терапии женской сексуальной дисфункции
UA111785C2 (uk) Композиція для лікування бородавок та спосіб лікування бородавок
UA69624U (uk) Спосіб профілактики загострення хронічного бронхіту у хворих зі сполученим перебігом з пептичною виразкою дванадцятипалої кишки
UA69222U (ru) Способ рефлексотерапии больных с отдаленными последствиями черепно-мозговой травмы
UA77030U (ru) Процесс профилактики и лечения реперфузионного синдрома при острой ишемии конечностеЙ
UA59989U (ru) Способ лечения больных стеатозом печени
UA74769U (ru) Способ лечения больных со стеатозом печени, совмещенным с хроническим безкаменным холециститом
WO2014170820A3 (en) A pharmaceutical combination for treating tuberculosis